Drugs / NBI-1117568
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04935320 | Jul → Oct 2021 | — | Nxera Pharma UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT04849286 | Sep → Dec 2018 | — | Nxera Pharma UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT03244228 | Aug 2017 → Sep 2019 | — | Nxera Pharma UK Limited | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT07288320 | Dec 2025 → Feb 2028 expected | bipolar I disorder, manic bipolar affective disorder | Neurocrine Biosciences | Recruiting | No outcome recorded |
| Phase 2 | NCT05545111 | Oct 2022 → Jul 2024 | schizophrenia | Neurocrine Biosciences | Completed | Met primary |
| Phase 34 trials | ||||||
| Phase 3 | NCT07227818 | Dec 2025 → Jul 2029 expected | schizophrenia | Neurocrine Biosciences | Recruiting | No outcome recorded |
| Phase 3 | NCT07105098 | Aug 2025 → Nov 2027 expected | schizophrenia | Neurocrine Biosciences | Recruiting | No outcome recorded |
| Phase 3 | NCT07114874 | Jul 2025 → Dec 2031 expected | schizophrenia | Neurocrine Biosciences | Recruiting | No outcome recorded |
| Phase 3 | NCT06963034 | May 2025 → Oct 2027 expected | schizophrenia | Neurocrine Biosciences | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-05-29 | Nxera Pharma UK Limited | Results Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 nxera.life ↗
Neurocrine Biosciences, Inc. announced that it had presented new positive data from the Phase 2 study of NBI -1117568 in adults with schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting in Scottsdale, Arizona. |
| 2024-08-28 | Nxera Pharma UK Limited | Results Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568 nxera.life ↗
NBI-1117568 (NBI-‘568) has delivered positive topline results from its Phase 2 clinical study in adults with schizophrenia. |
| 2024-08-28 | Nxera Pharma UK Limited | Results Other nxera.life ↗
NBI-1117568-SCZ2028 用量設定試験は、20mg 1日 1 回投与群で主要評価項目を達成しました。 |
| 2022-08-05 | Nxera Pharma UK Limited | Regulatory Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine nxera.life ↗ |
| 2022-08-05 | Nxera Pharma UK Limited | Regulatory Other nxera.life ↗ |
All press releases naming this drug 10 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NBI-1117568 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06963034 ↗ |
| Known as | HTL0016878 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03244228 ↗ |
| Route | Oral | “Oral solution” NCT03244228 ↗ |